CORDIS Project
Funding breakdown and partner intelligence are Premium
Sign in and upgrade to Premium for EU contribution totals, consortium analytics, OpenAlex research context, and AI summaries. · 0 consortium intelligence fields visible of 1
Start free • Cancel anytime • 14-day refund guarantee
The AllergyVAX project aims to improve allergen immunotherapy by developing modified hypoallergens. This technology seeks to reduce treatment duration and side effects for allergy sufferers, enhancing the effectiveness of long-term symptom relief.
Allergy is a rapidly increasing, global problem that already affects 1 billion people and causes significant social and economic burden.
In Europe, allergic rhinitis and asthma cause more than 100 million missed work and school days per year.
Allergy is usually managed by avoiding the allergen or by medication that temporarily alleviates the symptoms.
The only disease-modifying treatment available to date is allergen immunotherapy (AIT) where long-term symptom relief is achieved by training the…
Partner organizations (coordinator is shown above), with normalized type and CORDIS activity type. Guests see up to 4 partners.
Similar projects, consortium collaboration history, frequent partners, and OpenAlex research context.
Guests see up to 5 EuroSciVoc fields.
Guests see up to 5 topics.
